Anti-PCSK9 [FAP2M21]

Absolute Antibody

Anti-PCSK9 [FAP2M21]

7

This antibody binds human PCSK9 with an extremely slow dissociation rate constant and exert its hypolipidemic effect by blocking PCSK9-LDLR interaction. The binding characterization of this antibody was done using ELISA. Bio-Layer Interferometry (BLI) analysis revealed that the full-length IgG1 antibody FAP2M21 binds to hPCSK9 with a KD as low as 1.42 nM, and a dramatically slow dissociation rate (koff, 4.68 x 10-6 s-1) (PMID: 33647772). This antibody was also used to analyze LDLR expressed on the surface of HepG2 cells using flow cytometry and immunofluorescence staining. This antibody potently inhibited PCSK9-induced reduction of LDL-C uptake in HepG2 cells, with an EC50 of 43.56 nM. When this antibody was injected in C57BL/6 mice expressing human PCSK9, it dose-dependently up-regulated hepatic LDLR levels, and concomitantly reduced serum LDL-C by 3.3% and 37.2%, respectively (PMID: 33647772).

Functional Assay, Flow Cytometry, ImmunoFluorescence, ELISA, Neutralisation/Blocking

Research Use Only

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format for improved compatibility with existing reagents assays and techniques.

-20°C,2°C to 8°C

12352203